endpts.com·May 21, 2026
BioMarin Pharmaceutical plans to pursue expanded approval for its drug Voxzogo, which has shown to enhance growth speed in children with a specific type of short stature.
BioMarin Pharmaceutical's pursuit of expanded approval for Voxzogo, due to its success in improving growth speed in children with short stature, highlights a potential investment opportunity in the biotech sector, specifically in therapies targeting genetic growth disorders. This move also underlines the importance of monitoring FDA approval processes for drugs that address niche patient populations, which can significantly impact market dynamics and company valuation.